Switch from cyclosporine A to mycophenolate mofetil in nephrotic children

Pediatric Nephrology

Volumn 20, Issue 4, 2005, Pages 482-485

  Ulinski, Tim ^a   Dubourg, Laurence ^a   Saïd, Marie Hélène ^a   Parchoux, Bernadette ^a   Ranchin, Bruno ^a   Cochat, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Cyclosporine A (CyA); Inulin clearance; Mycophenolate mofetil (MMF); Nephrotic syndrome; Nephrotoxicity

Indexed keywords

CYCLOSPORIN A; INULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMA PROTEIN; PREDNISONE; STEROID;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; DIARRHEA; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GINGIVA HYPERTROPHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRICHOSIS; INULIN CLEARANCE; MALE; NEPHROTIC SYNDROME; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; REMISSION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GINGIVAL HYPERTROPHY; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; RETREATMENT; TREATMENT OUTCOME;

EID: 15344344185     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1778-4     Document Type: Article

References (17)

1. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D (2002) Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 17:2011-2013
2. Seikaly MG, Prashner H, Nolde-Hurlbert B, Browne R (2000) Long-term clinical and pathological effects of cyclosporin in children with nephrosis. Pediatr Nephrol 14:214-217
3. Allison AC, Eugui EM (1993) Immunosuppressive and other anti-rheumatic activities of mycophenolate mofetil. Agents Actions Suppl 44:165-188
4. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18:833-837
5. Montane B, Abitbol C, Chandar J, Strauss J, Zilleruelo G (2003) Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 18:772-777
6. Eugui EM, Mirkovich A, Allison AC (1991) Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23:15-18
7. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM (1993) Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 25:67-70
8. Allison AC, Eugui EM (1993) The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 14:353-380
9. Chang CC, Naiki M, Halpern GM, Gershwin ME (1993) Pharmacological regulation of the immune system. J Investig Allergol Clin Immunol 3:8-18
10. Chang CC, Aversa G, Punnonen J, Yssel H, de Vries JE (1993) Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro. Ann NY Acad Sci 696:108-122
11. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M (1999) Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14:58-63
12. Senda M, DeLustro B, Eugui E, Natsumeda Y (1995) Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 60:1143-1148
13. Cohn RG, Mirkovich A, Dunlap B, Burton P, Chiu SH, Eugui E, Caulfield JP (1999) Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 68:411-418
14. Penny MJ, Boyd RA, Hall BM (1998) Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition. J Am Soc Nephrol 9:2272-2282
15. Fujihara CK, De Lourdes Noronha I, Malheiros, Antunes GR, de Oliveira IB, Zatz R (2000) Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11:283-290
16. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G (1997) Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51:1583-1589
17. Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19:101-104